Dexmedetomidine for Double lumen tube insertio
Phase 3
- Conditions
- Health Condition 1: J852- Abscess of lung without pneumoniaHealth Condition 2: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
- Registration Number
- CTRI/2021/10/037238
- Lead Sponsor
- Christian Medical College Vellore
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients undergoing elective lung surgery, including pulmonary lobectomy, pneumonectomy, metastasectomy, decortication, etc. who require Left-sided DLT placement
2.Patients belonging to ASA physical status I to III
Exclusion Criteria
1.Patients with difficult airway.
2.Surgeries requiring Right sided Double-Lumen tube insertion.
3.Uncontrolled hypertensives.
4.Heart disease with ejection fraction less than 40%,
5.Body mass index (BMI) more than 35 kg/m2,
6.History suggestive of sensitivity to drugs used during the study
7.Patients with bradycardia (heart rate < 50 beat per minute) or any heart block
8.Hepatic or renal impairment
9.Pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint was to compare the hemodynamic responses(defined as a change in heart rate or systolic blood pressure or both by more than 20% of their baseline values prior to induction of anaesthesia) between dexmedetomidine and placebo given in addition to the drugs used in our current standard of care during laryngoscopy and DLT insertion.Timepoint: At baseline(Prior to any drug administration), at laryngoscopy and double lumen tube insertion(Which effectively happen at the same time) and every minute after intubation for the first five minutes, then every five minutes until placement of tube is confirmed by fiber-optic bronchoscopy
- Secondary Outcome Measures
Name Time Method